Crinetics Pharmaceuticals recently raised $102 million through an initial public offering. Standing right to left in Crinetics’ lab space that’s under construction: CEO Scott Struthers; chief financial officer Marc Wilson; and Steve Betz, a co-founder and vice president of biology.

Crinetics Pharmaceuticals recently raised $102 million through an initial public offering. Standing right to left in Crinetics’ lab space that’s under construction: CEO Scott Struthers; chief financial officer Marc Wilson; and Steve Betz, a co-founder and vice president of biology. Photo by Jamie Scott Lytle.

Crinetics Pharmaceuticals Inc.

CEO: Scott Struthers

No. of employees: 38

Year Founded: 2008

Stock symbol: CRNX on Nasdaq

Company Description: Crinetics is working on drugs for endocrine-related cancers and endocrine disorders

photo

Crinetics Pharmaceuticals in April expanded into this building at 10222 Barnes Canyon Road.

— After early years operating on a shoestring budget, Crinetics Pharmaceuticals is flush with cash to pursue ambitious drug development plans...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129